
Opinion|Videos|July 23, 2024
Private Label Biosimilars
The expert panel discusses the greater potential for private label biosimilars.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- Some healthcare companies are investigating the potential for private label biosimilars, including products like adalimumab. What is the value of offering a private label biosimilar to patients? What are some of the challenges that may arise?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Five Ways AI Is Transforming Cancer Care—and Companies That Are Making It Happen
2
Cefdinir Nearly Doubles Outpatient Uncomplicated UTI Treatment Failure Compared With Cephalexin
3
NIH F32 Grants Boost Early-Career Researchers’ Success
4
Nipocalimab Investigation Extends to Younger Patients: Jonathan Strober, MD
5













































